Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration

Abstract

Considerable part (19.4%) of the total cancer deaths (1.59 million deaths worldwide) in 2012 were related to lung cancer.1 It is estimated that more than 200,000 new cases of lung cancer will develop and up to 158,000 resulting deaths will ensue.2 Out of this large number, non–small cell Lung cancer (NSCLC) presents itself as the most common lung cancer (90%) and is associated with significant morbidity and mortality. Amid the genetic characteristics of NSCLC, echinoderm microtubule-associated protein-like 4 (EML4)–anaplastic lymphoma kinase (ALK) mutation, which translates into a fusion-type protein tyrosine kinase, offers a promising therapeutic interest.

Topics & Concepts